TL;DR
This paper reports on a workshop that brought together experts from North Asia to discuss the implementation of the WHO's global framework for viral hepatitis prevention and control. It highlights key priorities and challenges across four strategic axes: awareness, evidence, prevention, and treatment, emphasizing the need for collaborative, region-specific policies.
What Problem Does This Paper Address?
Viral hepatitis, particularly hepatitis B and C, remains a significant global health burden, disproportionately affecting Asia. Despite the existence of the World Health Organization's (WHO) "Framework for Global Action on Viral Hepatitis," its effective implementation across diverse regions like North Asia faces numerous hurdles. These include varying levels of public and professional awareness, challenges in data collection and utilization, difficulties in preventing transmission, and significant gaps in screening, care, and treatment access. This paper addresses the need to translate the global WHO framework into actionable, localized strategies tailored to the specific contexts of North Asian countries.
Methods
The study is based on the outcomes of a workshop organized by the Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP) in Taipei in October 2012. Twenty-eight representatives from liver associations, patient organizations, and centers of excellence in Hong Kong, Japan, Korea, and Taiwan participated. The workshop agenda was developed in consultation with CEVHAP experts and utilized the four axes of the WHO framework to guide discussions. Methods included expert presentations, group discussions, and country-level workshops. The paper then summarizes the findings and identifies steps for translating the WHO framework into national policies.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- The WHO Framework as a Blueprint: The WHO's framework provides a valuable global vision, but its success hinges on adaptation to local realities and collaborative efforts.
- Awareness is Paramount, but Nuance is Key: While raising public and professional awareness is crucial, campaigns need to be carefully crafted to avoid unintended negative consequences, such as stigma and discrimination, as seen in the Korean case study.
- Data Drives Policy, but Gaps Exist: Reliable epidemiological and economic data are essential for advocating for resources and informing policy. However, significant gaps remain in understanding the true prevalence, particularly in high-risk populations, and in identifying barriers to screening and treatment.
- Prevention is Multifaceted: While hepatitis B vaccination has been successful, ongoing monitoring and efforts to extend vaccination to at-risk groups are necessary. For hepatitis C, addressing injecting drug use as a primary transmission route and improving safe injection practices are critical.
- Screening and Treatment Linkage is a Major Hurdle: Even when screening is available, a significant proportion of those who test positive do not seek treatment. This highlights the need for better linkage to care, comprehensive care models, and addressing barriers like cost and lack of public funding.
- The Power of Advocacy and Partnerships: Strong patient advocacy networks and collaborations between clinical specialists, primary care physicians, and policymakers are vital for driving policy change and ensuring sustainable action.
Key Results
The workshop identified specific priorities for action within each of the four WHO framework axes for Hong Kong, Japan, Korea, and Taiwan. These include:
- Raising Awareness: Greater public and physician awareness, building patient advocacy, and strengthening hospital-primary care networks.
- Evidence-based Policy: Economic data on the burden of viral hepatitis, better data on screening/treatment barriers, centralized surveillance, and accurate case estimates.
- Prevention of Transmission: Better vaccine effectiveness monitoring, improved vaccination access, targeted harm reduction, and better data on vaccine failure.
- Screening, Care, and Treatment: Improved availability and funding for screening, linking screening to monitoring and treatment, funding for hepatocellular carcinoma screening, and improved access to chronic hepatitis and HCC treatment.
Case studies from the US ("KNOW More Hepatitis") and Korea illustrate effective (and sometimes problematic) approaches to public engagement. A case study from Japan highlights the power of patient advocacy in driving policy change. Another case study from Hong Kong demonstrates the positive impact of secure government funding on treatment access and compliance.
Limitations and Future Work
The paper acknowledges that the challenges identified are similar to those in other regions, suggesting that lessons learned can be shared globally. The authors emphasize the need for collaborative efforts involving primary care physicians, specialists, governments, at-risk individuals, and people living with viral hepatitis. They also suggest learning from successful public health campaigns in other disease areas (e.g., breast cancer, cardiovascular disease, HIV/AIDS) to raise the profile of viral hepatitis and develop comprehensive policies. Future work should focus on translating these identified priorities into concrete, impactful policies and interventions within each North Asian country.
Summary updated